The Safety and Effectiveness of Adefovir Dipivoxil in HIV-Infected Children
Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001
Trial Information
Current as of May 11, 2025
Completed
Keywords
ClinConnect Summary
Although the oral bioavailability of PMEA ( adefovir ) is low, the prodrug bis-POM PMEA has resulted in increased bioavailability in adult patients in clinical trials. However, the safety and pharmacokinetic patterns of drugs in infants often differ from those of adults and the direction of the variation is not predictable. This study will assess these parameters of bis-POM PMEA in children.
Patients are stratified by age, and separate cohorts from each age group receive 1 of 2 single doses of bis-POM PMEA. The lower dose is given to patients ages 3 months through 17 years; if toxicity is ...
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- Patients must have:
- • Asymptomatic or mildly symptomatic HIV infection, with no worse than grade 1 toxicity for any symptoms.
- • Consent of parent or guardian.
- Prior Medication:
- Allowed:
- • IV gammaglobulin and aerosolized pentamidine for PCP prophylaxis.
- • Antiretrovirals if discontinued by 72 hr prior to study entry.
- • Exclusion Criteria
- Co-existing Condition:
- Patients with the following symptoms or conditions are excluded:
- • Acute or chronic infections that require treatment during study.
- Concurrent Medication:
- Excluded:
- • Antiretrovirals other than study drug.
- • Other investigational agents.
- • Immunomodulators.
- • HIV-1 vaccines.
- • Glucocorticoids.
- • Drugs with potential for adverse interaction with study drug or that would interfere with quantitation of study drug in serum or plasma.
- • TMP / SMX and dapsone.
- PER AMENDMENT 8/23/96:
- * Drugs which may affect renal excretion:
- • Probenecid, Acyclovir, Ganciclovir, Foscarnet, Amphotericin B and Pentamidine.
- Prior Medication:
- Excluded within 72 hr prior to study entry:
- • Antiretrovirals other than study drug.
- • Other investigational agents.
- • Immunomodulators.
- • HIV-1 vaccines.
- • Glucocorticoids.
- • Drugs with potential for adverse interaction with study drug or that would interfere with quantitation of study drug in serum or plasma.
- • TMP / SMX and dapsone.
- PER AMENDMENT 8/23/96:
- * Drugs which may affect renal excretion:
- • Probenecid, Acyclovir, Ganciclovir, Foscarnet, Amphotericin B and Pentamidine.
About National Institute Of Allergy And Infectious Diseases (Niaid)
The National Institute of Allergy and Infectious Diseases (NIAID) is a key component of the National Institutes of Health (NIH) dedicated to advancing the understanding, prevention, and treatment of infectious and immune-mediated diseases. Through rigorous clinical trials, NIAID aims to foster innovative research that enhances public health and addresses global health challenges, including emerging infectious diseases and allergies. The institute collaborates with various partners, including academic institutions, industry, and international organizations, to translate scientific discoveries into effective therapies and vaccines. NIAID's commitment to high-quality clinical research is integral to improving health outcomes and informing policy decisions in the realm of infectious diseases and immunology.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Francisco, California, United States
Chicago, Illinois, United States
Baltimore, Maryland, United States
Boston, Massachusetts, United States
Newark, New Jersey, United States
Philadelphia, Pennsylvania, United States
Memphis, Tennessee, United States
San Juan, , Puerto Rico
Jacksonville, Florida, United States
Nashville, Tennessee, United States
Patients applied
Trial Officials
Hughes W
Study Chair
Shenep J
Study Chair
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials